Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

CLINICAL UPDATEChanges to the World Health Organization guideline on hormonal contraceptive eligibility for women at high risk of HIV: South African perspective and response

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • بيانات النشر:
      Health and Medical Publishing Group
    • الموضوع:
      2018
    • Collection:
      AJOL - African Journals Online
    • نبذة مختصرة :
      The World Health Organization (WHO) published guidelines for hormonal contraceptive eligibility for women at high risk of HIV in March 2017. This guidance followed from a technical consultative meeting convened by the WHO in December 2016, where all the available evidence on hormonal contraceptives and risk of HIV acquisition was reviewed. This was an expert meeting with representation from global experts in family planning and HIV management, including clinicians, epidemiologists, researchers and civil society. The guideline development group, through a consensus, made recommendations to change the medical eligibility criteria for contraceptive use from category 1 to category 2 for progestogen-only injectable contraceptives among women at high risk of HIV. There was no change in the recommendation for all other methods of hormonal contraception. The data that informed this decision are from observational studies, which have limitations; therefore, causality or association of hormonal contraception and risk of HIV acquisition have not been proven. This guidance will have an impact on countries that have a high HIV disease burden and where progestogen-only injectable contraceptives are the highest used, as in South Africa (SA). The information has to be communicated in line with the WHO’s sexual and reproductive health rights principles of ensuring that all women should receive evidence-based recommendations. This will empower them to make informed choices about their reproductive needs. This article seeks to clarify the decision-making process of the WHO and how the new recommendations were formulated. It also gives SA’s response to the guidance and a perspective of what informed the National Department of Health’s position, taking into account the effect this will have on SA’s contraceptive guidelines.S Afr Med J 2018;108(8):629-631
    • File Description:
      application/pdf
    • Relation:
      https://www.ajol.info/index.php/samj/article/view/178517/167899; https://www.ajol.info/index.php/samj/article/view/178517
    • الدخول الالكتروني :
      https://www.ajol.info/index.php/samj/article/view/178517
    • Rights:
      Copyright remains in the Author’s name. The work is licensed under a Creative Commons Attribution - Noncommercial Works License. Authors are required to complete and sign an Author Agreement form that outlines Author and Publisher rights and terms of publication. The Agreement form should be uploaded along with other submissions files and any submission will be considered incomplete without it [forthcoming].Material submitted for publication in the SAMJ is accepted provided it has not been published or submitted for publication elsewhere. Please inform the editorial team if the main findings of your paper have been presented at a conference and published in abstract form, to avoid copyright infringement. The SAMJ does not hold itself responsible for statements made by the authors.Previously published imagesIf an image/figure has been previously published, permission to reproduce or alter it must be obtained by the authors from the original publisher and the figure legend must give full credit to the original source. This credit should be accompanied by a letter indicating that permission to reproduce the image has been granted to the author/s. This letter should be uploaded as a supplementary file during submission.
    • الرقم المعرف:
      edsbas.AA2CA57E